BridgeBio Pharma (BBIO) Amortization of Deferred Charges (2024 - 2026)

BridgeBio Pharma has reported Amortization of Deferred Charges for 5 years, with the latest figure at $1.8 million in Q1 2026.

• Quarterly Amortization of Deferred Charges rose 83.0% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (up 6.99% YoY) and the FY2025 annual result came in at $4.9 million, down 34.32% from the prior year.
• Amortization of Deferred Charges retreated to $1.8 million in Q1 2026 per BBIO's latest filing, from $2.0 million in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $2.1 million in Q4 2024 and troughed at $490000.0 in Q3 2025.
• A 3-year average of $1.3 million and a median of $1.4 million in 2025 frame the typical range for Amortization of Deferred Charges.
• The sharpest annual moves came in 2025 and 2026: Amortization of Deferred Charges declined 5.13% in 2025, then jumped 83.0% in 2026.
• Over 3 years, Amortization of Deferred Charges stood at $2.1 million in 2024, then decreased by 5.13% to $2.0 million in 2025, then declined by 7.15% to $1.8 million in 2026.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $1.8 million, $2.0 million, and $490000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.